58
Participants
Start Date
October 31, 2013
Primary Completion Date
July 31, 2015
Study Completion Date
April 30, 2016
Sarilumab
Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
Prednisone
Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
Methotrexate
Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
Folic/folinic acid
Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
Placebo (for Sarilumab)
Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
Investigational Site Number 840005, Slingerlands
Investigational Site Number 203002, Prague
Investigational Site Number 380001, Milan
Investigational Site Number 792002, Istanbul
Investigational Site Number 792003, Istanbul
Investigational Site Number 792004, Izmir
Investigational Site Number 792006, Izmir
Investigational Site Number 380003, Padua
Investigational Site Number 380004, Reggio Emilia
Investigational Site Number 840007, Cleveland
Investigational Site Number 203001, Brno
Investigational Site Number 250001, Paris
Investigational Site Number 250002, Paris
Investigational Site Number 840006, Arlington
Investigational Site Number 840008, Worcester
Investigational Site Number 840009, Omaha
Investigational Site Number 724003, Barcelona
Investigational Site Number 724001, Barcelona
Investigational Site Number 792001, Ankara
Investigational Site Number 792005, Ankara
Lead Sponsor
Sanofi
INDUSTRY